Getinge AB (publ) (GNGBY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Getinge AB (publ) (GNGBY) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 47/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Getinge AB (publ) (GNGBY) Gesundheitswesen & Pipeline-Uebersicht
Getinge AB (publ) provides solutions for operating rooms, intensive-care units, and sterilization departments, with a global presence and focus on acute care, life science, and surgical workflows. The company's diverse product portfolio and extensive distribution network position it as a key player in the medical devices sector.
Investmentthese
Getinge AB (publ) presents a notable research candidate due to its established market position in the medical devices sector and its diversified product portfolio. The company's focus on acute care, life science, and surgical workflows provides exposure to multiple growth areas within healthcare. With a P/E ratio of 22.79 and a dividend yield of 2.43%, Getinge offers a blend of value and income. Ongoing catalysts include increasing demand for healthcare solutions driven by an aging global population and advancements in medical technology. However, potential risks include currency fluctuations and competition from other medical device manufacturers.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $5.43 billion reflects Getinge's significant presence in the medical device industry.
- Profit margin of 6.5% indicates efficient operations and profitability.
- Gross margin of 45.9% demonstrates the company's ability to maintain pricing power and manage costs.
- Dividend yield of 2.43% provides an income stream for investors.
- Beta of 0.88 suggests lower volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diversified product portfolio
- Global presence and distribution network
- Strong brand reputation
- Focus on innovation
Schwaechen
- Exposure to currency fluctuations
- Dependence on healthcare spending
- Competition from larger medical device companies
- Potential for product recalls
Katalysatoren
- Ongoing: Increasing demand for healthcare solutions driven by an aging global population.
- Ongoing: Advancements in medical technology and innovation.
- Upcoming: Potential strategic acquisitions to expand product portfolio and market reach.
- Ongoing: Expansion in emerging markets with developing healthcare infrastructure.
- Ongoing: Development of integrated solutions combining hardware, software, and services.
Risiken
- Potential: Currency fluctuations impacting revenue and profitability.
- Potential: Changes in healthcare regulations and reimbursement policies.
- Ongoing: Competition from other medical device manufacturers.
- Potential: Product recalls or safety concerns.
- Potential: Economic downturns affecting healthcare spending.
Wachstumschancen
- Expansion in Emerging Markets: Getinge can leverage its existing distribution network to expand its presence in emerging markets, where healthcare infrastructure is developing and demand for medical devices is increasing. This expansion can drive revenue growth and diversify the company's geographic exposure. The global medical device market is expected to reach $600 billion by 2028, offering significant opportunities for growth.
- Technological Innovation: Investing in research and development to introduce innovative products and solutions can drive growth and maintain a competitive edge. Focus areas include advanced surgical technologies, digital healthcare solutions, and personalized medicine. Continuous innovation will allow Getinge to capture market share and address evolving customer needs. Ongoing investment in R&D is crucial for long-term success.
- Strategic Acquisitions: Acquiring complementary businesses and technologies can expand Getinge's product portfolio and market reach. Strategic acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing the company's competitive position. Careful due diligence and integration are essential for successful acquisitions.
- Increased Focus on Life Science Solutions: The life science segment offers significant growth potential due to increasing demand for bioprocessing equipment and solutions. Getinge can capitalize on this trend by expanding its product offerings and strengthening its relationships with pharmaceutical and biotechnology companies. The global bioprocessing market is projected to reach $30 billion by 2027.
- Development of Integrated Solutions: Offering integrated solutions that combine hardware, software, and services can create value for customers and differentiate Getinge from competitors. Integrated solutions can improve efficiency, reduce costs, and enhance patient outcomes. This approach can also create recurring revenue streams through service contracts and software subscriptions.
Chancen
- Expansion in emerging markets
- Development of integrated solutions
- Strategic acquisitions
- Increasing demand for bioprocessing solutions
Risiken
- Changes in healthcare regulations
- Economic downturns
- Technological obsolescence
- Increased competition
Wettbewerbsvorteile
- Established brand reputation and long-standing relationships with customers.
- Extensive distribution network and global reach.
- Diversified product portfolio across multiple healthcare segments.
- Strong focus on innovation and research and development.
Ueber GNGBY
Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a global provider of medical technology solutions. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products for critical care, including anesthesia machines, ventilators, and cardiovascular surgery solutions. The Life Science segment provides equipment and systems for sterile transfer, bioprocessing, and laboratory applications. The Surgical Workflows segment focuses on solutions for operating rooms, such as surgical tables, lighting systems, and sterile supply management. Getinge serves a global customer base through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Its comprehensive product portfolio and global reach solidify its position as a key player in the healthcare industry.
Was das Unternehmen tut
- Provides equipment for operating rooms and intensive-care units.
- Offers sterilization solutions for healthcare facilities.
- Develops and manufactures bioprocessing systems for the life science industry.
- Provides surgical workflows solutions.
- Offers acute care therapies, including anesthesia and ventilation equipment.
- Provides sterile transfer systems and closure processing systems.
Geschaeftsmodell
- Sells medical devices and equipment to hospitals, clinics, and research institutions.
- Provides service and maintenance contracts for its equipment.
- Offers software solutions for managing surgical workflows and bioprocessing operations.
- Generates revenue through a network of proprietary sales companies, agents, and distributors.
Branchenkontext
Getinge AB (publ) operates in the medical devices industry, which is characterized by continuous innovation and increasing demand driven by an aging global population and rising healthcare expenditures. The industry is competitive, with key players including Abbott Laboratories (ABT), Align Technology (ALGN), and Bio-Rad Laboratories (BIO). Getinge's focus on acute care, life science, and surgical workflows positions it to capitalize on specific growth areas within the broader medical devices market.
Wichtige Kunden
- Hospitals and clinics
- Research institutions
- Pharmaceutical and biotechnology companies
- Sterilization departments
Finanzdaten
Chart & Info
Getinge AB (publ) (GNGBY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
-
Stocks That Hit 52-Week Highs On Friday
· 10. Jan. 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 26. Nov. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer GNGBY.
Kursziele
Wall-Street-Kurszielanalyse fuer GNGBY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von GNGBY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Fuehrung: Mattias Perjos
President & CEO
Mattias Perjos serves as the President and CEO of Getinge AB (publ). Prior to joining Getinge, he held various leadership positions at other companies in the healthcare and technology sectors. His experience includes roles in sales, marketing, and general management. Perjos has a strong track record of driving growth and improving operational efficiency.
Erfolgsbilanz: Under Mattias Perjos' leadership, Getinge has focused on strengthening its core business, expanding its presence in key markets, and investing in innovation. He has overseen the development and launch of new products and solutions, as well as strategic acquisitions to enhance the company's competitive position. His tenure has been marked by a commitment to improving patient outcomes and delivering value to shareholders.
Getinge AB (publ) ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. GNGBY represents shares of Getinge AB (publ), a Swedish company. As an ADR, GNGBY allows U.S. investors to invest in Getinge without the complexities of cross-border transactions. Dividends are converted to U.S. dollars before distribution.
- Heimatmarkt-Ticker: Nasdaq Stockholm, Sweden
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: GNGB
GNGBY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet the minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to listed companies.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Higher price volatility
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Established operating history
- Reputable management team
- Audited financial statements (if available)
- Positive news coverage or industry recognition
- Clear business model and value proposition
Was Anleger ueber Getinge AB (publ) (GNGBY) wissen wollen
What are the key factors to evaluate for GNGBY?
Getinge AB (publ) (GNGBY) currently holds an AI score of 47/100, indicating low score. Key strength: Diversified product portfolio. Primary risk to monitor: Potential: Currency fluctuations impacting revenue and profitability.. This is not financial advice.
How frequently does GNGBY data refresh on this page?
GNGBY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNGBY's recent stock price performance?
Recent price movement in Getinge AB (publ) (GNGBY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GNGBY overvalued or undervalued right now?
Determining whether Getinge AB (publ) (GNGBY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GNGBY?
Before investing in Getinge AB (publ) (GNGBY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GNGBY to a portfolio?
Potential reasons to consider Getinge AB (publ) (GNGBY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diversified product portfolio. Additionally: Global presence and distribution network. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of GNGBY?
Yes, most major brokerages offer fractional shares of Getinge AB (publ) (GNGBY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track GNGBY's earnings and financial reports?
Getinge AB (publ) (GNGBY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for GNGBY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- The information provided is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.